FDA Finds No Evidence Weight-Loss Drugs Cause Suicidal Thoughts
Portfolio Pulse from Erica Kollmann
The FDA's preliminary review found no evidence that weight-loss drugs, specifically GLP-1 RAs, cause suicidal thoughts. This class includes Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound. The FDA cannot definitively rule out a small risk and will continue its investigation. The European Medicines Agency is also reviewing semaglutide, the active ingredient in Wegovy and Ozempic, after reports of suicidal thoughts.
January 11, 2024 | 9:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's Zepbound is part of the GLP-1 RAs class of drugs that the FDA's preliminary review found no evidence of causing suicidal thoughts, with further review pending.
The FDA's initial report is a positive development for Eli Lilly, suggesting Zepbound does not cause suicidal thoughts. However, the ongoing nature of the review means there is still some risk, which could affect the stock's short-term performance.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
FDA's preliminary review found no evidence that Novo Nordisk's weight-loss drugs Wegovy and Ozempic cause suicidal thoughts, but the investigation is ongoing.
The FDA's preliminary findings are positive for Novo Nordisk, potentially alleviating concerns about the safety of Wegovy and Ozempic. However, ongoing investigations mean there is still some uncertainty, which could limit the positive impact on the stock price.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80